nach oben

Journal of Public Health

Erschienen in:

01.08.2008 | Review Article

The role of scientific societies in the decision-making process to recommend new vaccines: the example of rotavirus in Europe

verfasst von: Timo Vesikari

Erschienen in: Journal of Public Health | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Aim

By taking the example of rotavirus in Europe, the aim of this article is to review the role of scientific societies in the decision-making process to recommend new vaccines.

Subjects and methods

The guidelines for rotavirus vaccination issued by the European Society for Paediatric Diseases (ESPID) and the European Society for Paediatric Gastroenterology, Hepatitis and Nutrition (ESPGHAN) Expert Group are examined in the light of the methodology used and recommendations previously issued in the US.

Results

The experience of the ESPID-ESPGHAN Expert Group was largely positive. The group was supported equally by the two vaccine manufacturers involved in rotavirus vaccine production (Sanofi Pasteur MSD, Glaxo SmithKline). However, while benefiting from the input of manufacturers, the expert group developed its recommendations independently both from the industry and regulatory authorities in Europe.

Conclusion

With a new vaccine, there is always a lack of expertise at the country level. Gaps in knowledge can be overcome by information and discussion in order to increase awareness of disease and available interventions. The ESPID-ESPGHAN Expert Group recommendations for rotavirus vaccine in Europe constitute the first evidence-based attempt of its kind.

I (Vesikari) selected the members of the original expert group. Representatives from ESPID and ESPGHAN were subsequently selected by the respective societies.

Advisory Committee on Immunisation Practices (ACIP) (2006) Prevention of rotavirus gastroenteritis in infants and children. Recommendations of the Advisory Committee on Immunisation Practices. MMWR 55:1–13

American Academy of Pediatrics (AAP) Committee on Infectious Diseases (2007) Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine. Pediatria 119:171–182CrossRef

Atkins D, Best D, Briss P, Eccles M, Falck-Ytter Y, GRADE Working Group (2004) Grading quality of evidence and strength of recommendation. BMJ 328:1490–1498PubMedCrossRef

CDC (1999) Intussusception among recipients of rotavirus vaccine-United States, 1998–1999. MMRW 48:577–581

Joensuu J, Koskenniemi E, Pang X-L, Vesikari T (1997) Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 350:1205–1209PubMedCrossRef

Pediatric ROTavirus European CommitTee (PROTECT) (2006) The paediatric burden of rotavirus disease in Europe. Epidemiol Infect 134:908–916CrossRef

Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M, Human Rotavirus Vaccine Study Group.Instituto Nacional de Ciencas (2006) Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354:11–22PubMedCrossRef

Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ (2005) More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 192(Suppl 1):S36–43PubMedCrossRef

Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T (2006) Burden of rotavirus disease in European Union countries. Pediatr Inf Dis J 25(Suppl):S7–S11CrossRef

Vesikari T, Isolauri E, D'Hondt E, Delem A, André FE, Zissis G (1984) Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1:977–981PubMedCrossRef

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM, Rotavirus Efficacy and Safety Trial (REST) Study Team (2006) Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354:23–33PubMedCrossRef

Vesikari T, van Damme P, Giaquinto C, Gray J, Mrukowicz J, Dagan R, Guarino A, Szajewska H, Usonis V (in press) ESPID/ESPGHAN evidence-based recommendation for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr Suppl.

Titel: The role of scientific societies in the decision-making process to recommend new vaccines: the example of rotavirus in Europe
verfasst von: Timo Vesikari
Publikationsdatum: 01.08.2008
Verlag: Springer-Verlag
Erschienen in: Journal of Public Health / Ausgabe 4/2008
Print ISSN: 2198-1833
Elektronische ISSN: 1613-2238
DOI: https://doi.org/10.1007/s10389-008-0205-x

Springer Medizin

Abstract

Aim

Subjects and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Public health economics of vaccines in the Netherlands: methodological issues and applications

How do we tackle the complex field of vaccinology in the twenty-first century?

The introduction of policies for human papillomavirus vaccination in Europe

The expected impact of new vaccines and vaccination policies

Funding processes for new vaccines: the need for greater understanding of the economic issues

The public perception of the value of vaccines - the case of Switzerland